Evidence map›Paper›PMID 39421926›Full record

ArticleCirculation research2024

Ferroptosis-Mediated Inflammation Promotes Pulmonary Hypertension.

Felipe Kazmirczak, Neal T Vogel, Sasha Z Prisco, Michael T Patterson, Jeffrey Annis, Ryan T Moon, Lynn M Hartweck, Jenna B Mendelson, Minwoo Kim, Natalia Calixto Mancipe and 9 more

Abstract read
In one paragraph

Article in Circulation research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.

0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

48 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Regulated Cell Death in Idiopathic Pulmonary Fibrosis.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026
    Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Felipe Kazmirczak *Minneapolis Heart Institute, MN (F.K.).
Neal T Vogel *Cardiovascular Division, Department of Medicine, Lillehei Heart Institute (N.T.V., S.Z.P., R.T.M., L.M.H., J.B.M., M.K., B.K., M.L.B., K.W.P.), University of Minnesota, Minneapolis, MN.
Sasha Z Prisco *Cardiovascular Division, Department of Medicine, Lillehei Heart Institute (N.T.V., S.Z.P., R.T.M., L.M.H., J.B.M., M.K., B.K., M.L.B., K.W.P.), University of Minnesota, Minneapolis, MN.ORCID 0000-0002-9059-0635
Michael T PattersonCenter for Immunology (M.T.P., J.W.W.), University of Minnesota, Minneapolis, MN.
Jeffrey AnnisDepartment of Medicine, Vanderbilt University Medical Center, Nashville, TN (J.A., E.L.B.).ORCID 0000-0002-3097-4186
Ryan T MoonCardiovascular Division, Department of Medicine, Lillehei Heart Institute (N.T.V., S.Z.P., R.T.M., L.M.H., J.B.M., M.K., B.K., M.L.B., K.W.P.), University of Minnesota, Minneapolis, MN.
Lynn M HartweckCardiovascular Division, Department of Medicine, Lillehei Heart Institute (N.T.V., S.Z.P., R.T.M., L.M.H., J.B.M., M.K., B.K., M.L.B., K.W.P.), University of Minnesota, Minneapolis, MN.ORCID 0000-0002-7926-3342
Jenna B MendelsonCardiovascular Division, Department of Medicine, Lillehei Heart Institute (N.T.V., S.Z.P., R.T.M., L.M.H., J.B.M., M.K., B.K., M.L.B., K.W.P.), University of Minnesota, Minneapolis, MN.ORCID 0000-0002-8229-385X
Minwoo KimCardiovascular Division, Department of Medicine, Lillehei Heart Institute (N.T.V., S.Z.P., R.T.M., L.M.H., J.B.M., M.K., B.K., M.L.B., K.W.P.), University of Minnesota, Minneapolis, MN.
Natalia Calixto MancipeMinnesota Supercomputing Institute (N.C.M.), University of Minnesota, Minneapolis, MN.ORCID 0000-0002-2558-1126
Todd MarkowskiDepartment of Biochemistry, Molecular Biology, and Biophysics, Center for Metabolomics and Proteomics (T.M., L.H., C.G.), University of Minnesota, Minneapolis, MN.ORCID 0000-0001-9157-2036
LeeAnn HigginsDepartment of Biochemistry, Molecular Biology, and Biophysics, Center for Metabolomics and Proteomics (T.M., L.H., C.G.), University of Minnesota, Minneapolis, MN.
Candace GuerreroDepartment of Biochemistry, Molecular Biology, and Biophysics, Center for Metabolomics and Proteomics (T.M., L.H., C.G.), University of Minnesota, Minneapolis, MN.
Ben KremerCardiovascular Division, Department of Medicine, Lillehei Heart Institute (N.T.V., S.Z.P., R.T.M., L.M.H., J.B.M., M.K., B.K., M.L.B., K.W.P.), University of Minnesota, Minneapolis, MN.
Madelyn L BlakeCardiovascular Division, Department of Medicine, Lillehei Heart Institute (N.T.V., S.Z.P., R.T.M., L.M.H., J.B.M., M.K., B.K., M.L.B., K.W.P.), University of Minnesota, Minneapolis, MN.ORCID 0000-0002-6802-9470
Christopher J RhodesNational Heart and Lung Institute, Imperial College, London, United Kingdom (C.J.R.).ORCID 0000-0002-4962-3204
Jesse W WilliamsCenter for Immunology (M.T.P., J.W.W.), University of Minnesota, Minneapolis, MN.ORCID 0000-0003-3815-0891
Evan L BrittainDepartment of Medicine, Vanderbilt University Medical Center, Nashville, TN (J.A., E.L.B.).ORCID 0000-0001-5843-3392
Kurt W PrinsCardiovascular Division, Department of Medicine, Lillehei Heart Institute (N.T.V., S.Z.P., R.T.M., L.M.H., J.B.M., M.K., B.K., M.L.B., K.W.P.), University of Minnesota, Minneapolis, MN.ORCID 0000-0002-0364-6742

Funding

TRAINING PROGRAM IN MUSCLE RESEARCHT32AR007612 · NIAMS · UNIVERSITY OF MINNESOTA TWIN CITIES · PI JAMES M ERVASTI, DAWN A LOWE · 2001 to 2026
$11.3M
Clinical and Mechanistic Understanding of Right Ventricular Steatosis in Pulmonary Arterial HypertensionR01HL155278 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Evan L Brittain · 2022 to 2026
$3.8M
Effect of PDE5 Inhibition on Adipose Metabolism in HumansR01DK124845 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BRITTAIN, EVAN L, DAMON, BRUCE M. · 2021 to 2025
$3.4M
Clinical, Genetic, and Proteomic Risk Factors for Pulmonary Hypertension in Heart FailureR01HL146588 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BRITTAIN, EVAN L, FREIBERG, MATTHEW S · 2019 to 2022
$3.4M
Network Medicine and Systems Pharmacology to Advance Precision Medicine in Combined Pulmonary HypertensionR01HL163960 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Evan L Brittain, Anna R Hemnes · 2022 to 2026
$3.4M
GP130 Antagonism in Porcine RV Pressure OverloadR01HL162927 · NHLBI · UNIVERSITY OF MINNESOTA · PI Kurt W Prins · 2022 to 2026
$3.3M
Multi-scale Investigation of Sex Differences in Right Ventricular Function via Estrogen-Microtubule InteractionsR01HL158795 · NHLBI · UNIVERSITY OF MINNESOTA · PI Kurt W Prins · 2022 to 2026
$2.8M
Sex and stress hormones control adrenal gland macrophage development and function"R01AI165553 · NIAID · UNIVERSITY OF MINNESOTA · PI WILLIAMS, JESSE WARREN · 2022 to 2025
$2.2M
Regulation of Foamy Macrophage Differentiation and Survival in AtherosclerosisR01HL166843 · NHLBI · UNIVERSITY OF MINNESOTA · PI Jesse Warren Williams · 2024 to 2026
$1.6M
A transformative next-generation Orbitrap Tribrid system for the UMN and Upper MidwestS10OD028717 · OD · UNIVERSITY OF MINNESOTA · PI GRIFFIN, TIMOTHY J. · 2020 to 2020
$1.2M
The MObile Health InterVEntion in Pulmonary Arterial Hypertension (MOVE PAH) StudyR61HL158941 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BRITTAIN, EVAN L · 2022 to 2022
$773k
Modulating the Microbiome to Enhance Right Ventricular Function in Pulmonary Arterial HypertensionK08HL168166 · NHLBI · UNIVERSITY OF MINNESOTA · PI Sasha Zheng Prisco · 2024 to 2026
$525k
FDA HHS R01 FD007627NHLBI NIH HHS F31 HL170585NHLBI NIH HHS K08 HL168166NHLBI NIH HHS R01 HL146588NHLBI NIH HHS R01 HL155278NHLBI NIH HHS R01 HL158795NHLBI NIH HHS R01 HL162927NHLBI NIH HHS R01 HL163960NHLBI NIH HHS R01 HL166843NHLBI NIH HHS R61 HL158941NIAID NIH HHS R01 AI165553NIAMS NIH HHS T32 AR007612NIDDK NIH HHS R01 DK124845NIH HHS S10 OD028717
6 · The paper itself

Abstract

backgroundMitochondrial dysfunction, characterized by impaired lipid metabolism and heightened reactive oxygen species generation, results in lipid peroxidation and ferroptosis. Ferroptosis is an inflammatory mode of cell death that promotes complement activation and macrophage recruitment. In pulmonary arterial hypertension (PAH), pulmonary arterial endothelial cells exhibit cellular phenotypes that promote ferroptosis. Moreover, there is ectopic complement deposition and inflammatory macrophage accumulation in the pulmonary vasculature. However, the effects of ferroptosis inhibition on these pathogenic mechanisms and the cellular landscape of the pulmonary vasculature are incompletely defined.

methodsMultiomics and physiological analyses evaluated how ferroptosis inhibition-modulated preclinical PAH. The impact of adeno-associated virus 1-mediated expression of the proferroptotic protein ACSL (acyl-CoA synthetase long-chain family member) 4 on PAH was determined, and a genetic association study in humans further probed the relationship between ferroptosis and pulmonary hypertension.

resultsFerrostatin-1, a small-molecule ferroptosis inhibitor, mitigated PAH severity in monocrotaline rats. RNA-sequencing and proteomics analyses demonstrated ferroptosis was associated with PAH severity. RNA-sequencing, proteomics, and confocal microscopy revealed complement activation and proinflammatory cytokines/chemokines were suppressed by ferrostatin-1. In addition, ferrostatin-1 combatted changes in endothelial, smooth muscle, and interstitial macrophage abundance and gene activation patterns as revealed by deconvolution RNA-sequencing. Ferroptotic pulmonary arterial endothelial cell damage-associated molecular patterns restructured the transcriptomic signature and mitochondrial morphology, promoted the proliferation of pulmonary artery smooth muscle cells, and created a proinflammatory phenotype in monocytes in vitro. Adeno-associated virus 1-

conclusionsFerroptosis promotes PAH through metabolic and inflammatory mechanisms in the pulmonary vasculature.

Indexed as

CyclohexylaminesFerroptosisAnimalsCells, CulturedCoenzyme A LigasesEndothelial CellsHumansHypertension, PulmonaryInflammationLong-Chain-Fatty-Acid-CoA LigaseMacrophagesMaleMonocrotalinePhenylenediaminesPulmonary ArteryRatsCoenzyme A LigasesCyclohexylaminesferrostatin-1Long-Chain-Fatty-Acid-CoA LigaseMonocrotalinePhenylenediaminescardiovascular diseasesferroptosishypertension, pulmonarymitochondria

Identifiers

PMID39421926
PMCPMC11560515

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.